https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=19329

Sofosbuvir / Velpatasvir / Voxilaprevir

Omeprazole

Potential interaction.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Omeprazole by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of velpatasvir .

Sofosbuvir / Velpatasvir / Voxilaprevir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Monitor for clinical efficacy.

Alternative solution(s)

–

Omeprazole

Pharmacodynamic effects

–

Recommendations

PPI doses should not exceed comparable to omeprazole 20 mg QD either dexlansoprazole 30 mg; esomeprazole 20 mg; lansoprazole 30 mg; pantoprazole 40 mg; rabeprazole 20 mg.

Alternative solution(s)

–

Monitor

–

Tests

–

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir / Voxilaprevir
3379 3379
34 34
- -
400/100/100 mg 400/100/100 mg
x 1 x 1
- 27%/- 54%/- 20% † - 18%/- 51%/- 5% ††
- 23%/- 57%/- 24% † - 6%/- 51%/+ 8% ††
Omeprazole
3379 3379
34 34
- -
20 mg 20 mg
QD * QD **
   
   
Comment

Ref #3379 : * Omeprazole administred 2 hours before sofosbuvir/velpatasvir/voxilaprevir;
** Omeprazole administred 4 hours after sofosbuvir/velpatasvir/voxilaprevir;
† GS-331007 : AUC -3% and Cmax +27%;
†† GS-331007 : AUC -1% and Cmax +19%.

Comment
Reference
  • 3379
    Sofosbuvir/Velpatasvir/Voxilaprevir (VOSEVI), Gilead, Ontario, Canada, 28 janvier 2020.